发布求助
文献互助 智能选刊 最新文献

Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets 在化疗引起的血小板减少症中背诵这句箴言：治疗患者，而不是血小板。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-06-09 DOI: 10.1038/s41571-026-01170-x
Javier-David Benitez-Fuentes, Laure-Anne Teuwen, Bishal Gyawali
{"title":"RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets","authors":"Javier-David Benitez-Fuentes, Laure-Anne Teuwen, Bishal Gyawali","doi":"10.1038/s41571-026-01170-x","DOIUrl":"10.1038/s41571-026-01170-x","url":null,"abstract":"Recent data from the RECITE trial indicating that the thrombopoietin receptor agonist romiplostim ameliorates chemotherapy-induced thrombocytopenia offer hope for the first drug treatment for this condition. However, the ultimate goal is not to improve platelet counts but patient outcomes, and RECITE does not offer evidence of survival or quality-of-life benefits that truly matter to patients.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 8","pages":"562-563"},"PeriodicalIF":94.6,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Realizing the benefits of tumour-agnostic access requires a national health learning system 实现肿瘤不可知论获取的好处需要一个全国性的卫生学习系统。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-06-08 DOI: 10.1038/s41571-026-01167-6
Samuel X. Stevens, Deme J. Karikios
{"title":"Realizing the benefits of tumour-agnostic access requires a national health learning system","authors":"Samuel X. Stevens, Deme J. Karikios","doi":"10.1038/s41571-026-01167-6","DOIUrl":"10.1038/s41571-026-01167-6","url":null,"abstract":"The Australian Pharmaceutical Benefits Advisory Committee’s decision to allow tumour-agnostic reimbursement of nivolumab and ipilimumab is a bold experiment that involves a considerable level of risk-sharing between government, industry, clinicians and patients. The central policy challenge now is whether Australia has sufficient infrastructure and initiative to convert this access into timely and decision-relevant evidence. Reimbursement that accelerates access despite uncertainty carries an obligation to learn.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 8","pages":"560-561"},"PeriodicalIF":94.6,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does ciltacabtagene autoleucel have a future in multiple myeloma? 西他tagene autoeucel在多发性骨髓瘤中有前景吗？
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-06-08 DOI: 10.1038/s41571-026-01159-6
Ghulam Rehman Mohyuddin, Edward R. Scheffer Cliff, Rajshekhar Chakraborty
{"title":"Does ciltacabtagene autoleucel have a future in multiple myeloma?","authors":"Ghulam Rehman Mohyuddin, Edward R. Scheffer Cliff, Rajshekhar Chakraborty","doi":"10.1038/s41571-026-01159-6","DOIUrl":"10.1038/s41571-026-01159-6","url":null,"abstract":"Ciltacabtagene autoleucel (cilta-cel) has transformed the outcomes of patients with relapsed or refractory multiple myeloma, yet its toxicity profile — spanning acute and delayed-onset neurotoxicity, secondary malignancies, immune effector-cell colitis, infections and prolonged cytopenias — has emerged slowly. As safer alternatives become available, the risk–benefit calculus for cilta-cel demands urgent reassessment, particularly in earlier lines of therapy.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 9","pages":"649-651"},"PeriodicalIF":94.6,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ibrutinib improves overall survival in patients with mantle cell lymphoma 伊鲁替尼提高套细胞淋巴瘤患者的总生存率。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-06-03 DOI: 10.1038/s41571-026-01166-7
Peter Sidaway
{"title":"Ibrutinib improves overall survival in patients with mantle cell lymphoma","authors":"Peter Sidaway","doi":"10.1038/s41571-026-01166-7","DOIUrl":"10.1038/s41571-026-01166-7","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 7","pages":"475-475"},"PeriodicalIF":94.6,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA 一线zanidatamab化疗联合或不联合tislelizumab可提高晚期HER2+ GEA患者的生存率。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-06-02 DOI: 10.1038/s41571-026-01169-4
Diana Romero
{"title":"First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA","authors":"Diana Romero","doi":"10.1038/s41571-026-01169-4","DOIUrl":"10.1038/s41571-026-01169-4","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 7","pages":"476-476"},"PeriodicalIF":94.6,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC KIM-1作为RCC血液生物标志物的现有证据和未来方向。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-05-20 DOI: 10.1038/s41571-026-01163-w
Wenxin Xu, Joseph V. Bonventre, Toni K. Choueiri
{"title":"Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC","authors":"Wenxin Xu, Joseph V. Bonventre, Toni K. Choueiri","doi":"10.1038/s41571-026-01163-w","DOIUrl":"10.1038/s41571-026-01163-w","url":null,"abstract":"Kidney injury molecule-1 (KIM-1) is overexpressed in renal cell carcinoma (RCC), and consistent shedding of this cell-surface protein into the circulation makes it a promising blood-based biomarker for this disease. Herein, we outline potential roles of circulating KIM-1 in diagnosis, prognostication and therapeutic monitoring of RCC, as well as research priorities for clinical translation of this biomarker.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 8","pages":"557-559"},"PeriodicalIF":94.6,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons 胃食管腺癌围手术期治疗的转变：胜利、挫折和未来的前景。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-05-15 DOI: 10.1038/s41571-026-01156-9
Hongcheng Zhu, Florian Lordick, Yelena Y. Janjigian, Sun Young Rha, Magnus Nilsson, Kohei Shitara, Richard Owen, Zhen Zhang, Elizabeth C. Smyth
{"title":"Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons","authors":"Hongcheng Zhu, Florian Lordick, Yelena Y. Janjigian, Sun Young Rha, Magnus Nilsson, Kohei Shitara, Richard Owen, Zhen Zhang, Elizabeth C. Smyth","doi":"10.1038/s41571-026-01156-9","DOIUrl":"10.1038/s41571-026-01156-9","url":null,"abstract":"The landscape of gastro-oesophageal adenocarcinoma (GEA) management has undergone substantial transformation over the past decade owing to shifts in epidemiology, evolving treatment paradigms and the integration of new therapeutic strategies. The global burden of GEA continues to rise, with differing patterns observed in Asia compared with Western countries. Important insights gleaned from recent high-profile clinical trials — both successful and negative — have considerably reshaped perioperative treatment strategies, redefining the roles of chemotherapy, radiotherapy, immune checkpoint inhibitors and targeted therapies. Although still investigational, organ-preserving approaches and circulating tumour DNA (ctDNA)-based patient stratification are shaping the direction of future GEA management. By consolidating these developments, this Review aims to provide clinicians and researchers with a comprehensive and structured guide to the state-of-the-art perioperative management of GEA, emphasizing the underlying biology, clinical implications and future directions. The management of gastro-oesophageal adenocarcinoma (GEA) is undergoing substantial changes owing to evolving treatment paradigms and new therapeutic strategies on the background of a shifting global epidemiology. This Review discusses the state-of-the-art perioperative management of resectable GEA, with an emphasis on how biological heterogeneity influences geographical practice patterns, and outlines future directions for research including precision medicine approaches, biomarker-guided immunotherapy and tailored surgical approaches.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 8","pages":"603-618"},"PeriodicalIF":94.6,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer 泛ras抑制剂daraxonrasib显示胰腺癌治疗前景
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-05-14 DOI: 10.1038/s41571-026-01162-x
David Killock
{"title":"Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer","authors":"David Killock","doi":"10.1038/s41571-026-01162-x","DOIUrl":"10.1038/s41571-026-01162-x","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 7","pages":"475-475"},"PeriodicalIF":94.6,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implementation of multi-cancer early detection tests: can we find a path forward? 临床实施多癌早期检测试验：能否找到前进的道路？
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-05-14 DOI: 10.1038/s41571-026-01158-7
Ariadna Tibau, Aaron S. Kesselheim
{"title":"Clinical implementation of multi-cancer early detection tests: can we find a path forward?","authors":"Ariadna Tibau, Aaron S. Kesselheim","doi":"10.1038/s41571-026-01158-7","DOIUrl":"10.1038/s41571-026-01158-7","url":null,"abstract":"On 3 February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was enacted, enabling Medicare coverage for multi-cancer early detection (MCED) tests. This legislation coincides with new results from key clinical trials and has important implications for payers and policymakers, given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 7","pages":"473-474"},"PeriodicalIF":94.6,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer 液体活检告知新辅助化疗期间的辅助决策-鼻咽癌的一个完整的循环时刻。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-05-06 DOI: 10.1038/s41571-026-01157-8
W. K. Jacky Lam, Brigette B. Y. Ma
{"title":"Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer","authors":"W. K. Jacky Lam, Brigette B. Y. Ma","doi":"10.1038/s41571-026-01157-8","DOIUrl":"10.1038/s41571-026-01157-8","url":null,"abstract":"The historical development of plasma Epstein–Barr virus DNA for informing clinical decisions for patients with nasopharyngeal carcinoma has culminated in the EP-STAR trial. The circulating tumour DNA clearance patterns observed during neoadjuvant chemotherapy could be used to guide adjuvant therapy, improve outcomes and possibly reflect differences in tumour biology. Herein we discuss why this study constitutes a full-circle moment and provides valuable insights for advancing circulating tumour DNA-based applications in precision oncology.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 7","pages":"479-480"},"PeriodicalIF":94.6,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书